Chronic Kidney Disease Market Insight 2034

DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Discover Key Insights into the Chronic Kidney Disease Market with DelveInsight's In-Depth Report @ Chronic Kidney Disease Market Size

Key Takeaways from the Chronic Kidney Disease Market Report

• In Sept 2025, eGenesis received FDA clearance for its Investigational New Drug (IND) application to start clinical trials of EGEN-2784, a genetically engineered porcine kidney, for treating end-stage kidney disease (ESKD). The Phase 1/2/3 study will evaluate safety and efficacy in dialysis-dependent patients aged 50 and older on the transplant waitlist.

• In March 2025, the FDA expanded the approval of Furoscix to include the treatment of edema in patients with chronic kidney disease, including nephrotic syndrome.

• Among the 7MM, the US accounted for approximately 52% of the total Chronic Kidney Disease market size in 2023, with EU4 and the UK for 38%, and Japan for 10%.

• In the EU4 and the UK, in 2023, more females were affected than males, with approximately 3,550 thousand female cases and 3,400 thousand male cases.

• In Japan, in 2023, the Chronic Kidney Disease Therapeutics Market Size was estimated to be about USD 1,402 million.

• As per DelveInsight estimates, in 2023, the US had nearly 40 million prevalent cases of Chronic Kidney Disease, expected to increase by 2034.

• The leading Chronic Kidney Disease Companies such as ProKidney, Reata Pharmaceuticals Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.

• Promising Chronic Kidney Disease Pipeline Therapies such as Ziltivekimab, Zibotentan/Dapagliflozin, Baxdrostat/dapagliflozin, Vicadrostat + Empagliflozin, Lorundrostat, Rilparencel, BI 690517 + Empagliflozin, Ocedurenone (KBP-5074), and others.

Stay ahead in the Chronic Kidney Disease Therapeutics Market with DelveInsight's Strategic Report @ Chronic Kidney Disease Market Outlook

Chronic Kidney Disease Epidemiology Segmentation in the 7MM

• Total Prevalent Cases of Chronic Kidney Disease

• Total Diagnosed Prevalent Cases of Chronic Kidney Disease

• Gender-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Age-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Complication-specific Prevalent Cases of Chronic Kidney Disease

• Severity-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Etiology-specific Diagnosed Prevalent Cases of Chronic Kidney Disease

• Total Diagnosed Prevalent Cases of CKD in the 7MM

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Prevalence

Chronic Kidney Disease Marketed Drugs

• KERENDIA (finerenone): Bayer HealthCare Pharmaceuticals Inc.
  KERENDIA is a nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with Chronic Kidney Disease associated with type 2 diabetes. In February 2022, KERENDIA was granted market authorization by the European Commission for the treatment of chronic kidney disease (with albuminuria) associated with Type 2 diabetes mellitus in adults.

• INVOKANA (canagliflozin): Janssen Research & Development, LLC
  INVOKANA (canagliflozin) is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. INVOKANA is the class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors, approved in the United States in 2013. The label was expanded to cover more indications such as diabetic kidney disease in the subsequent years in the US along with EU and Japan.

Chronic Kidney Disease Emerging Drugs

• Ocedurenone (KBP-5074): KBP Biosciences
  Ocedurenone (KBP-5074) is a nonsteroidal MRA discovered and developed by KBP Biosciences. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than recombinant human glucocorticoid, progesterone, and androgen receptors, which can produce antihypertensive, renal, and cardioprotective effects. Currently, the Phase III clinical trial for Ocedurenone's first indication—advanced Chronic Kidney Disease and uncontrolled hypertension—is in progress.

• BI 690517 + Empagliflozin: Boehringer Ingelheim
  BI 690517 is a novel, potent, highly selective aldosterone synthase inhibitor (ASi), which is intended to slow the progression of kidney damage and to reduce cardiovascular events in people with CKD. The compound was discovered and developed by Boehringer Ingelheim and is part of its research and development portfolio in cardiovascular-renal-metabolic conditions.

Get In-Depth Knowledge on Chronic Kidney Disease Market Trends and Forecasts with DelveInsight @ Chronic Kidney Disease Treatment Market

Chronic Kidney Disease Market Outlook
Chronic Kidney Disease is a long-term condition characterized by a gradual loss of kidney function over time. It is commonly caused by diabetes and hypertension, which damage the blood vessels in the kidneys. Symptoms often include fatigue, swelling, and changes in urination. CKD progresses through five stages, from mild damage (stage 1) to kidney failure (stage 5), also known as end-stage renal disease (ESRD). Early detection through blood and urine tests is crucial for managing the disease.

Chronic Kidney Disease Drugs Market Insights
Chronic Kidney Disease treatment aims to manage symptoms, slow progression, and reduce complications. It typically includes lifestyle changes such as a balanced diet low in sodium, regular exercise, and cessation of smoking. Medications may be prescribed to control blood pressure, blood sugar, and cholesterol. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are often used to protect kidney function. For advanced CKD, dialysis or kidney transplantation may be necessary. Regular monitoring and early intervention are crucial to managing CKD effectively. Collaborative care involving nephrologists, dietitians, and primary care providers enhances treatment outcomes.

Scope of the Chronic Kidney Disease Market Report

• Coverage: 7MM

• Study Period: 2020-2034

• Chronic Kidney Disease Companies: ProKidney, Reata Pharmaceuticals Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, AstraZeneca, Allena Pharmaceuticals, DiaMedica Therapeutics Inc., Lexicon Pharmaceuticals, Sanofi, and others.

• Chronic Kidney Disease Pipeline Therapies: Ziltivekimab, Zibotentan/Dapagliflozin, Baxdrostat/dapagliflozin, Vicadrostat + Empagliflozin, Lorundrostat, Rilparencel, BI 690517 + Empagliflozin, Ocedurenone (KBP-5074), and others.

• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease Market Drivers and Barriers

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Kidney Disease Market Report @ Chronic Kidney Disease Market Drivers and Barriers

Table of Contents

1. Key Insights

2. Report Introduction

3. CKD Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Key Events

6. Executive Summary of CKD

7. Disease Background and Overview of Chronic Kidney Disease (CKD)

8. Epidemiology and Patient Population of CKD

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. CKD: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. SWOT Analysis

15. Unmet needs

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us 

Kanishk

kkumar@delveinsight.com